Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Fuji
Colorcon
Farmers Insurance
QuintilesIMS
McKesson

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,896,509

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,896,509
Title:Use of antagonists of the interaction between HIV GP120 and .alpha.4.beta.7 integrin
Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.1 or .beta.7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
Inventor(s): Arthos; James (Bethesda, MD), Goode; Diana (Bellingham, MA), Cicala; Claudia (Bethesda, MD), Fauci; Anthony S. (Bethesda, MD)
Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)
Application Number:15/227,879
Patent Claims:see list of patent claims

Details for Patent 9,896,509

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) 2027-03-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,896,509

Country Patent Number Publication Date
European Patent Office 2109480 Jun 28, 2017
European Patent Office 2109480 Oct 21, 2009
United States of America 2011086024 Apr 14, 2011
United States of America 2016075786 Mar 17, 2016
United States of America 2016333097 Nov 17, 2016
United States of America 9193790 Nov 24, 2015
United States of America 9441041 Sep 13, 2016
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Queensland Health
Fish and Richardson
Boehringer Ingelheim
Healthtrust
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.